EG 427

Executive Summary

EG 427 is a French biotechnology company founded in 2019 that is developing next-generation precision molecular therapies for chronic diseases using a proprietary non-replicative Herpes Simplex Virus 1 (nrHSV-1) vector platform. This vector enables safe, durable, and redosable delivery of large therapeutic genes, addressing a key limitation of many gene therapy approaches. The company's initial focus is on underserved peripheral nervous system disorders, where its platform can deliver targeted treatments with improved safety and efficacy. With its innovative technology and experienced team, EG 427 is poised to advance its lead programs toward clinical development, positioning itself as a potential leader in gene therapies for neurological conditions.

Upcoming Catalysts (preview)

• 2026IND/CTA Filing for Lead Program60% success
• Q3 2026Preclinical Proof-of-Concept Data in Peripheral Neuropathy Model80% success
• TBDPartnership or Licensing Deal for nrHSV-1 Platform40% success